Antibody-Drug Conjugate

MADRID — A novel antibody-drug conjugate plus osimertinib showed clinical activity and a manageable safety profile in patients with relapsed/refractory, EGFR-mutated non-small cell lung cancer, according to a presentation at ESMO Congress.

After decades of developmental challenges, antibody-drug conjugates have emerged as potentially less toxic and more effective treatment options for a variety of malignancies.

Healio spoke with Ahmed Elkhanany, MD, about treatment options available in metastatic triple-negative breast cancer.

Healio spoke with Ahmed Elkhanany, MD, about recent advancements in metastatic triple-negative breast cancer.

Doctoral researchers from 11 European institutions and four companies have formed a research network dedicated to developing molecules that stimulate the immune response to tumor cells.

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.

Use of different antibody-drug conjugates resulted in a variety of significant and in some cases serious treatment‐associated adverse events, according to results of a systematic review and meta-analysis published in Cancer.

The advent of novel therapies has propelled, and continues to propel, tremendous progress and innovation in diffuse large B-cell lymphoma.

In this video, Kevin Kalinsky, MD, discussed new data on antibody-drug conjugates, including sacituzumab, presented at 39th Miami Breast Cancer Conference.